摘要
Abstract
Objective:To evaluate the efficacy of anlotinib in combination with standard paclitaxel plus cisplatin(TP)chemotherapy in patients with advanced progressive non-small cell lung cancer(NSCLC),and to explore its effects on serum inflammatory cytokines and tumor markers.Methods:A retrospective analysis was conducted on 94 patients with advanced progressive NSCLC who were diagnosed and received systematic treatment in our hospital from April 2020 to April 2025.Among them,47 patients received standard TP chemo-therapy(control group),while the other 47 patients received TP chemotherapy combined with oral anlotinib(observation group).Tumor response and safety were compared between the two groups,and the patients were followed up for 12 months to assess survival outcomes,including progression-free survival(PFS)and overall survival(OS).Survival curves were plotted using the Kaplan-Meier method,and PFS and OS of the two groups were compared through the Log-rank test.Serum levels of tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment(Cyfra21-1)]and inflammatory factors[interleukin-2(IL-2),IL-10,interferon-γ(IFN-γ)]were measured before treatment and after four cycles of therapy.Results:After treatment,the disease con-trol rate(DCR)in the observation group was significantly higher than that in the control group(P＜0.05).Regarding safety,the overall incidence of proteinuria and hypertension in the observation group during treatment was higher than that in the control group(P＜0.05).Follow-up results showed that the control group had a PFS of 6.95±1.71 months with 28 deaths and an OS of 7.42±1.67 months;the observation group had a PFS of 8.26±2.34 months with 17 deaths and an OS of 10.63±1.92 months.Differences between the two groups were statistically significant(x2=7.986,8.012,P＜0.05).After treatment,levels of CEA,CA125,Cyfra21-1,and IL-10 decreased in both groups,whereas IL-2 and IFN-γ increased compared with pre-treatment levels,with more pronounced changes observed in the observation group(P＜0.05).Conclusion:The addition of anlotinib to TP chemotherapy significantly improves disease control,extends PFS and OS,and modulates tumor marker levels and inflammatory responses in advanced progressive NSCLC,suggesting a poten-tial immunomodulatory role in the tumor microenvironment.However,anlotinib is associated with increased risks of proteinuria and hyper-tension,warranting careful monitoring and individualized management.关键词
非小细胞肺癌/晚期进展/紫杉醇-顺铂/安罗替尼/生存获益/炎症因子/肿瘤标志物Key words
Non-small cell lung cancer/Advanced progression/Paclitaxel-cisplatin/Anlotinib/Survival benefit/Inflammatory cytokines/Tumor markers分类
医药卫生
